{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:21:36Z","timestamp":1790918496264,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1743-422x-8-153","type":"journal-article","created":{"date-parts":[[2011,4,6]],"date-time":"2011-04-06T15:01:02Z","timestamp":1302102062000},"source":"Crossref","is-referenced-by-count":21,"title":["Inhibition of HCV 3a core gene through Silymarin and its fractions"],"prefix":"10.1186","volume":"8","author":[{"given":"Usman Ali","family":"Ashfaq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Javed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidra","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafar","family":"Nawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheikh","family":"Riazuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,4,1]]},"reference":[{"key":"1264_CR1","first-page":"4","volume":"41","author":"NSJK Raja","year":"2008","unstructured":"Raja NSJK: Epidemiology of hepatitis C virus infection in Pakistan. J Microbiol Immunol Infect. J Microbiol Immunol Infect 2008, 41: 4-8.","journal-title":"J Microbiol Immunol Infect"},{"key":"1264_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1046\/j.1365-2893.1999.6120139.x","volume":"6","author":"WHO","year":"1999","unstructured":"WHO: Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999, 6: 35-47. 10.1046\/j.1365-2893.1999.6120139.x","journal-title":"J Viral Hepat"},{"key":"1264_CR3","first-page":"S3","volume":"36","author":"KM Scannell","year":"2002","unstructured":"Scannell KM, Willard CC, Seeff LB: National Institutes of Health Consensus Development Conference Statement: management of hepatitis C. Hepatology 2002, 36: S3-S20.","journal-title":"Hepatology"},{"key":"1264_CR4","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00268-007-9041-3","volume":"31","author":"Y Barazani","year":"2007","unstructured":"Barazani Y, Hiatt JR, Tong MJ, Busuttil RW: Chronic viral hepatitis and hepatocellular carcinoma. World J Surg 2007, 31: 1243-1248. 10.1007\/s00268-007-9041-3","journal-title":"World J Surg"},{"key":"1264_CR5","first-page":"642","volume":"39","author":"NH Saleem","year":"2008","unstructured":"Saleem NH, Adrien A, Razaque A: Risky sexual behavior, knowledge of sexually transmitted infections and treatment utilization among a vulnerable population in Rawalpindi, Pakistan. Southeast Asian J Trop Med Public Health 2008, 39: 642-648.","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"1264_CR6","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/j.1365-2893.2006.00742.x","volume":"13","author":"M Karmochkine","year":"2006","unstructured":"Karmochkine M, Carrat F, Dos Santos O, Cacoub P, Raguin G: A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. J Viral Hepat 2006, 13: 775-782. 10.1111\/j.1365-2893.2006.00742.x","journal-title":"J Viral Hepat"},{"key":"1264_CR7","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1001\/jama.289.18.2413","volume":"289","author":"SL Flamm","year":"2003","unstructured":"Flamm SL: Chronic hepatitis C virus infection. Jama 2003, 289: 2413-2417. 10.1001\/jama.289.18.2413","journal-title":"Jama"},{"key":"1264_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11894-002-0034-y","volume":"4","author":"M Cornberg","year":"2002","unstructured":"Cornberg M, Wedemeyer H, Manns MP: Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. Curr Gastroenterol Rep 2002, 4: 23-30. 10.1007\/s11894-002-0034-y","journal-title":"Curr Gastroenterol Rep"},{"key":"1264_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1046\/j.1365-2125.1998.00836.x","volume":"46","author":"S Khakoo","year":"1998","unstructured":"Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, Murray-Lyon I, Lypnyj D, Flannery B, Walters K, Dusheiko GM: Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998, 46: 563-570. 10.1046\/j.1365-2125.1998.00836.x","journal-title":"Br J Clin Pharmacol"},{"key":"1264_CR10","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/S0016-5085(03)00394-9","volume":"124","author":"MW Russo","year":"2003","unstructured":"Russo MW, Fried MW: Side effects of therapy for chronic hepatitis C. Gastroenterology 2003, 124: 1711-1719. 10.1016\/S0016-5085(03)00394-9","journal-title":"Gastroenterology"},{"key":"1264_CR11","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1053\/j.gastro.2007.02.038","volume":"132","author":"SJ Polyak","year":"2007","unstructured":"Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, Lee DY: Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology 2007, 132: 1925-1936. 10.1053\/j.gastro.2007.02.038","journal-title":"Gastroenterology"},{"key":"1264_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65: 55-63. 10.1016\/0022-1759(83)90303-4","journal-title":"J Immunol Methods"},{"key":"1264_CR13","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","volume":"339","author":"JG McHutchison","year":"1998","unstructured":"McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339: 1485-1492. 10.1056\/NEJM199811193392101","journal-title":"N Engl J Med"},{"key":"1264_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1001\/archderm.140.2.215","volume":"140","author":"MM Moore","year":"2004","unstructured":"Moore MM, Elpern DJ, Carter DJ: Severe, generalized nummular eczema secondary to interferon alfa-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Arch Dermatol 2004, 140: 215-217. 10.1001\/archderm.140.2.215","journal-title":"Arch Dermatol"},{"key":"1264_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0166-3542(87)90084-2","volume":"8","author":"M Amoros","year":"1987","unstructured":"Amoros M, Fauconnier B, Girre RL: In vitro antiviral activity of a saponin from Anagallis arvensis, Primulaceae, against herpes simplex virus and poliovirus. Antiviral Res 1987, 8: 13-25. 10.1016\/0166-3542(87)90084-2","journal-title":"Antiviral Res"},{"key":"1264_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/0042-6822(92)90294-Y","volume":"187","author":"XJ Yao","year":"1992","unstructured":"Yao XJ, Wainberg MA, Parniak MA: Mechanism of inhibition of HIV-1 infection in vitro by purified extract of Prunella vulgaris. Virology 1992, 187: 56-62. 10.1016\/0042-6822(92)90294-Y","journal-title":"Virology"},{"key":"1264_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0009-2797(94)90006-X","volume":"91","author":"MP Miguez","year":"1994","unstructured":"Miguez MP, Anundi I, Sainz-Pardo LA, Lindros KO: Hepatoprotective mechanism of silymarin: no evidence for involvement of cytochrome P450 2E1. Chem Biol Interact 1994, 91: 51-63. 10.1016\/0009-2797(94)90006-X","journal-title":"Chem Biol Interact"},{"key":"1264_CR18","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/sj.onc.1208276","volume":"24","author":"RP Singh","year":"2005","unstructured":"Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R: Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene 2005, 24: 1188-1202. 10.1038\/sj.onc.1208276","journal-title":"Oncogene"},{"key":"1264_CR19","doi-asserted-by":"publisher","first-page":"8641","DOI":"10.1158\/1078-0432.CCR-04-1435","volume":"10","author":"RP Singh","year":"2004","unstructured":"Singh RP, Mallikarjuna GU, Sharma G, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R: Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin Cancer Res 2004, 10: 8641-8647. 10.1158\/1078-0432.CCR-04-1435","journal-title":"Clin Cancer Res"},{"key":"1264_CR20","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/mc.20223","volume":"45","author":"RP Singh","year":"2006","unstructured":"Singh RP, Agarwal R: Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog 2006, 45: 436-442. 10.1002\/mc.20223","journal-title":"Mol Carcinog"},{"key":"1264_CR21","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.2165\/00003495-200161140-00003","volume":"61","author":"R Saller","year":"2001","unstructured":"Saller R, Meier R, Brignoli R: The use of silymarin in the treatment of liver diseases. Drugs 2001, 61: 2035-2063. 10.2165\/00003495-200161140-00003","journal-title":"Drugs"},{"key":"1264_CR22","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/mc.1032","volume":"30","author":"Y Sharma","year":"2001","unstructured":"Sharma Y, Agarwal C, Singh AK, Agarwal R: Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells. Mol Carcinog 2001, 30: 224-236. 10.1002\/mc.1032","journal-title":"Mol Carcinog"},{"key":"1264_CR23","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1572-0241.2003.07298.x","volume":"98","author":"J Liu","year":"2003","unstructured":"Liu J, Manheimer E, Tsutani K, Gluud C: Medicinal herbs for hepatitis C virus infection: a Cochrane hepatobiliary systematic review of randomized trials. Am J Gastroenterol 2003, 98: 538-544. 10.1111\/j.1572-0241.2003.07298.x","journal-title":"Am J Gastroenterol"},{"key":"1264_CR24","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/01.mcg.0000174023.73472.29","volume":"39","author":"A Melhem","year":"2005","unstructured":"Melhem A, Stern M, Shibolet O, Israeli E, Ackerman Z, Pappo O, Hemed N, Rowe M, Ohana H, Zabrecky G, et al.: Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial. J Clin Gastroenterol 2005, 39: 737-742. 10.1097\/01.mcg.0000174023.73472.29","journal-title":"J Clin Gastroenterol"},{"key":"1264_CR25","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1158\/1535-7163.MCT-07-0104","volume":"6","author":"S Roy","year":"2007","unstructured":"Roy S, Kaur M, Agarwal C, Tecklenburg M, Sclafani RA, Agarwal R: p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther 2007, 6: 2696-2707. 10.1158\/1535-7163.MCT-07-0104","journal-title":"Mol Cancer Ther"},{"key":"1264_CR26","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.jhep.2009.02.023","volume":"50","author":"M Trappoliere","year":"2009","unstructured":"Trappoliere M, Caligiuri A, Schmid M, Bertolani C, Failli P, Vizzutti F, Novo E, di Manzano C, Marra F, Loguercio C, Pinzani M: Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol 2009, 50: 1102-1111. 10.1016\/j.jhep.2009.02.023","journal-title":"J Hepatol"},{"key":"1264_CR27","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1053\/j.gastro.2008.07.072","volume":"135","author":"P Ferenci","year":"2008","unstructured":"Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, Schoniger-Hekele M, Holzmann H, Steindl-Munda P: Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon\/ribavirin therapy. Gastroenterology 2008, 135: 1561-1567. 10.1053\/j.gastro.2008.07.072","journal-title":"Gastroenterology"},{"key":"1264_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/hep.20032","volume":"39","author":"F Penin","year":"2004","unstructured":"Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM: Structural biology of hepatitis C virus. Hepatology 2004, 39: 5-19. 10.1002\/hep.20032","journal-title":"Hepatology"},{"key":"1264_CR29","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/2053","volume":"4","author":"K Moriya","year":"1998","unstructured":"Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K: The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998, 4: 1065-1067. 10.1038\/2053","journal-title":"Nat Med"},{"key":"1264_CR30","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1136\/gut.2003.038364","volume":"53","author":"O Nunez","year":"2004","unstructured":"Nunez O, Fernandez-Martinez A, Majano PL, Apolinario A, Gomez-Gonzalo M, Benedicto I, Lopez-Cabrera M, Bosca L, Clemente G, Garcia-Monzon C, Martin-Sanz P: Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut 2004, 53: 1665-1672. 10.1136\/gut.2003.038364","journal-title":"Gut"},{"key":"1264_CR31","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/hep.510290355","volume":"29","author":"H Koga","year":"1999","unstructured":"Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, Harada M, Kusaba T, Tanaka M, Kimura R, et al.: Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999, 29: 688-696. 10.1002\/hep.510290355","journal-title":"Hepatology"},{"key":"1264_CR32","first-page":"1325","volume":"7","author":"MA Rahman","year":"2001","unstructured":"Rahman MA, Dhar DK, Yamaguchi E, Maruyama S, Sato T, Hayashi H, Ono T, Yamanoi A, Kohno H, Nagasue N: Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res 2001, 7: 1325-1332.","journal-title":"Clin Cancer Res"},{"key":"1264_CR33","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1074\/jbc.R300030200","volume":"279","author":"S Wormald","year":"2004","unstructured":"Wormald S, Hilton DJ: Inhibitors of cytokine signal transduction. J Biol Chem 2004, 279: 821-824. 10.1074\/jbc.R300030200","journal-title":"J Biol Chem"},{"key":"1264_CR34","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/hep.21782","volume":"46","author":"M Persico","year":"2007","unstructured":"Persico M, Capasso M, Persico E, Svelto M, Russo R, Spano D, Croce L, La Mura V, Moschella F, Masutti F, et al.: Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy. Hepatology 2007, 46: 1009-1015. 10.1002\/hep.21782","journal-title":"Hepatology"},{"key":"1264_CR35","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.1182\/blood-2002-12-3647","volume":"101","author":"LC Platanias","year":"2003","unstructured":"Platanias LC: Map kinase signaling pathways and hematologic malignancies. Blood 2003, 101: 4667-4679. 10.1182\/blood-2002-12-3647","journal-title":"Blood"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1743-422X-8-153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1743-422X-8-153\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1743-422X-8-153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T16:25:33Z","timestamp":1548174333000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/1743-422X-8-153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1264"],"URL":"https:\/\/doi.org\/10.1186\/1743-422x-8-153","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,1]]},"article-number":"153"}}